- Title: Subtitle
- 12M Interim Analysis of an Open-Label, Non-Randomized Extension of a Phase 2 Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Iptacopan in Subjects With C3G: TH-PO505
- Creators
- Carla M. Nester - University of IowaUte Eisenberger - University of Duisburg-EssenAlexandre Karras - Hôpital EuropéenLiz Lightstone - Imperial College LondonManuel Praga - Hospital Universitario 12 De OctubreGiuseppe Remuzzi - Mario Negri Institute for Pharmacological ResearchMaria Jose Soler - Vall d'Hebron Hospital UniversitariJunhao Liu - Novartis Pharmaceuticals Corporation, East Hanover, NJMatthias Meier - NovartisRonda Tawfik - Novartis Pharmaceuticals Corporation, East Hanover, NJGuido Junge - NovartisAndrea Biondani - NovartisAngelo J. Trapani - Novartis Pharmaceuticals Corporation, East Hanover, NJNicholas Webb - NovartisEdwin K. Wong - University of Newcastle Australia
- Resource Type
- Abstract
- Publication Details
- Journal of the American Society of Nephrology, Vol.33(11S), pp.190-190
- DOI
- 10.1681/ASN.20223311S1190b
- ISSN
- 1046-6673
- eISSN
- 1533-3450
- Language
- English
- Date published
- 11/2022
- Academic Unit
- Internal Medicine; Stead Family Department of Pediatrics; Nephrology, Dialysis and Transplantation
- Record Identifier
- 9984648569402771
Abstract
12M Interim Analysis of an Open-Label, Non-Randomized Extension of a Phase 2 Study to Evaluate the Long-Term Efficacy, Safety, and Tolerability of Iptacopan in Subjects With C3G: TH-PO505
Journal of the American Society of Nephrology, Vol.33(11S), pp.190-190
11/2022
DOI: 10.1681/ASN.20223311S1190b
Details
Metrics
7 Record Views